Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Metrics to compare | IMTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −1.4x | −0.5x | |
PEG Ratio | 0.00 | −0.18 | 0.00 | |
Price/Book | 2.3x | 1.3x | 2.6x | |
Price / LTM Sales | 22.7x | 6.1x | 3.1x | |
Upside (Analyst Target) | 90.9% | 476.9% | 57.5% | |
Fair Value Upside | Unlock | 26.3% | 8.6% | Unlock |